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Abstract
Ciliary neurotrophic factor (CNTF) is a potent neuroprotective cytokine in different animal models of glutamate-induced
excitotoxicity, although its action mechanisms are still poorly characterized. We tested the hypothesis that an increased
function of glial glutamate transporters (GTs) could underlie CNTF-mediated neuroprotection. We show that neuronal loss
induced by in vivo striatal injection of the excitotoxin quinolinic acid (QA) was significantly reduced (by ,75%) in CNTF-
treated animals. In striatal slices, acute QA application dramatically inhibited corticostriatal field potentials (FPs), whose
recovery was significantly higher in CNTF rats compared to controls (,40% vs. ,7%), confirming an enhanced resistance to
excitotoxicity. The GT inhibitor DL-threo-b-benzyloxyaspartate greatly reduced FP recovery in CNTF rats, supporting the role
of GT in CNTF-mediated neuroprotection. Whole-cell patch-clamp recordings from striatal medium spiny neurons showed
no alteration of basic properties of striatal glutamatergic transmission in CNTF animals, but the increased effect of a low-
affinity competitive glutamate receptor antagonist (c-D-glutamylglycine) also suggested an enhanced GT function. These
data strongly support our hypothesis that CNTF is neuroprotective via an increased function of glial GTs, and further
confirms the therapeutic potential of CNTF for the clinical treatment of progressive neurodegenerative diseases involving
glutamate overflow.
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Introduction
Ciliary neurotrophic factor (CNTF) is a neurotrophic cytokine
belonging to the interleukin-6 type family. In the CNS, CNTF is
released by astrocytes and stimulates the survival of developing
neurons. CNTF is also neuroprotective in various models of acute
neuronal death and neurodegenerative diseases [1], and it has
been proposed as a neuroprotective agent for Huntington’s disease
(HD) [2]. In HD, glutamate receptor-mediated excitotoxicity is
involved in the preferential loss of striatal medium-sized spiny
neurons (MSNs). Neurons expressing high levels of NMDA
receptors are lost early from the striatum of individuals affected
with HD, and injection of NMDA receptor agonists such as
quinolinic acid (QA) into the striatum of rodents or non-human
primates mimics the pattern of neuronal damage observed in HD
[3,4]. CNTF administration in the striatum protects MSNs against
QA in rodents and primates [5–7]. A phase I clinical trial confirmed
the safety of local brain administration of encapsulated cells
genetically engineered to produce CNTF and reported a recovery
of somatosensory evoked potentials in patient implanted with
capsules releasing the largest amount of CNTF [8]. Despite these
encouraging results, the mechanisms mediating CNTF neuropro-
tective effect are still unclear. The change in astrocyte phenotype
triggered by CNTF in the adult brain suggests that this cytokine
may have an indirect neuroprotective effect through activated
astrocytes [9–11]. Indeed, we have recently shown that CNTF-
activated astrocytes display marked phenotypic and molecular
changes associated with an improved handling of extracellular
glutamate in the rat striatum [12]. We suggested that such effect
could be mediated by an increased function of astrocyte glutamate
transporters (GTs), GLAST and GLT-1. These two GTs uptake the
bulk of extracellular glutamate [13] and this function is crucial to
prevent accumulation of glutamate to excitotoxic levels. Using
lentivirus-mediated CNTF overexpression in the rat striatum,
whole-cell patch-clamp and extracellular electrophysiological re-
cordings on corticostriatal slices, we provide evidence that CNTF
neuroprotective effects against QA are mediated through an en-
hanced glutamate uptake by activated astrocytes.
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CNTF Activates Astrocytes and Protects Striatal Neurons
against QA Excitotoxicity In Vivo and In Slices
We first confirmed that CNTF activated striatal astrocytes
[12,14]. We observed a marked re-expression of vimentin and the
overexpression of GFAP (Fig. 1A) in CNTF rats. To evaluate
CNTF neuroprotective effects against excitotoxicity, we used QA,
which stimulates NMDA receptors and triggers glutamate outflow
[15,16]. QA was injected in the striatum of Vehicle, LacZ and
CNTF rats and the volume of QA-induced lesions was measured
on NeuN stained sections (N=8-9/group) 2 weeks later. Lesion
volume (Fig. 1B) was significantly smaller in the CNTF group
(1.9160.81 mm
3) compared to both Vehicle (8.8560.99 mm
3)
and LacZ (8.3760.90 mm
3).
We then tested the acute effect of QA application on FP
recorded from corticostriatal slices. QA is known to induce a
strong reduction in the amplitude of corticostriatal FP, followed by
a partial recovery upon washout [17–19]. As shown in Fig. 2A,
application of 1 mM QA for 5 min quickly depressed FP in slices
from both LacZ and CNTF rats (N=14 and 16, respectively).
During QA washout, FP progressively and partially recovered in
both groups. However, FP recovery was significantly improved in
CNTF slices (Fig. 2B). For example, after 30 min QA washout, FP
recovered only to 765% of the initial value in LacZ, but up to
43611% in CNTF slices (p,0.05, Mann-Whitney test; Fig. 2B).
To control that the improved FP recovery in CNTF rats was not
due to a different basal synaptically-evoked glutamatergic activity,
we measured the input/output ratio as the ratio of the presynaptic
volley amplitude to the associated FP amplitude, before QA
application. As shown in Fig. 2A inset, the input/output ratio was
not significantly different between LacZ (1.4360.25) and CNTF
slices (1.2460.28) (p.0.05, Mann-Whitney test). These data
clearly show that CNTF overexpression in the striatum is
neuroprotective against QA excitotoxicity.
CNTF-Mediated Neuroprotection Is Not Due to Changes
in Striatal Glutamatergic Transmission
Since the excitotoxic effect of QA is due to both glutamate
release and NMDA receptor activation, we tested several
parameters of basal glutamatergic transmission. Paired pulse
ratio (PPR) of corticostriatal EPSCs (40 ms inter-EPSC interval;
EPSC2/EPSC1) was not significantly different between LacZ
(0.8560.15; N=10) and CNTF (0.9560.08; N=10) slices
(p.0.05, Mann-Whitney test), indicating that glutamate release
probability was not altered by CNTF (Fig. 3A). Frequency and
amplitude of spontaneous EPSCs (sEPSCs) were also not changed
by CNTF (Fig. 3B): average sEPSC frequency was 4.6261.5 and
4.0262.6 Hz, and average amplitude was 8.2463.10 and
8.4562.5 pA, respectively in LacZ and CNTF slices (N=10 and
p.0.05 for both frequency and amplitude, Mann-Whitney test).
Finally, NMDA/AMPA ratio (Fig. 3C) was not significantly
different between CNTF and LacZ slices (0.4960.06, N=31, and
0.4260.04, N=37, respectively, p.0.05, Student’s t-test). These
data suggest that the neuroprotective effects of CNTF are not due
to major changes in glutamatergic transmission, glutamate release,
and AMPA and NMDA receptor function.
CNTF Overexpression Enhances Glial GT Function
We then tested whether CNTF affected the function of GTs, as
suggested by our microdialysis experiment showing improved
handling of glutamate outflow in the rat brain [12]. We first used
c-D-glutamylglycine (c-DGG), a low-affinity competitive glutamate
receptor antagonist whose action is sensitive to the concentration
and/or time-course of glutamate in the synaptic cleft [20]. The
inhibitory effect of this drug is thus directly correlated to the
efficacy of glutamate uptake: the more efficient the glutamate
uptake, the stronger the c-DGG effect [21]. Interestingly, the
effect of c-DGG (0.5 mM for 10 min) was significantly stronger in
Figure 1. CNTF activates astrocytes and protects striatal
neurons against QA excitotoxicity in vivo.A :CNTF activates
astrocytes that re-express vimentin (red) and overexpress GFAP around
GFP-positive MSNs neurons of the striatum. B: rats from Vehicle (Veh.),
LacZ and CNTF groups were injected with 80 nmol QA and the lesion (*)
volume was assessed 15 days later on NeuN-immunostained sections.
CNTF significantly decreased lesion size (
1p,0.001 vs. Veh. and LacZ
groups, ANOVA and Scheffe ´’s test).
doi:10.1371/journal.pone.0008550.g001
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between EPSC amplitude in the presence of c-DGG and in
control conditions was 0.7460.11 and 0.5860.07 in LacZ (N=6)
and CNTF (N=9) slices, respectively (p,0.05, Mann-Whitney
test). These data indicate that CNTF overexpression reduces the
relative concentration and/or time course of glutamate in the
synaptic cleft, suggesting an enhanced glutamate uptake. To
determine whether neuronal GTs were involved, we measured
Figure 2. CNTF partially prevents QA-induced FP reduction in
corticostriatal slices. A: time-course of the effect of QA on striatal FP
amplitude in LacZ vs. CNTF slices. Note how FP loss in CNTF is
attenuated and the recovery improved compared to LacZ. The inset
shows that the input/output ratio (volley/FP) is similar in both groups.
B: FP amplitude at different times in the two groups: FP recovery after
QA washout is significantly improved in CNTF compared to LacZ rats
(*p,0.05, **p,0.01, Mann-Whitney test).
doi:10.1371/journal.pone.0008550.g002
Figure 3. Properties of glutamatergic synaptic transmission
recorded from striatal MSNs. No significant changes in PPR (A), average
sEPSC frequency and amplitude (B), and NMDA/AMPA ratio (C)w e r e
observed between LacZ and CNTF slices. Traces: A: representative paired
pulse-evoked EPSCs (normalized on the first black EPSC); B: examples of
sEPSCs recordings; C: representative example of EPSCs recorded from a
striatal MSNs (LacZ) showing where the AMPA and NMDA receptor-
mediated component of the EPSC was measured (gray dots); note that after
50 ms (upper gray dot) the AMPA component is negligible, as shown by the
trace in the presence of AP-5 (40 mM). HP in A and B was 260 mV.
doi:10.1371/journal.pone.0008550.g003
CNTF Enhances Glutamate Uptake
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modulated by EAAC1 in the striatum [22]. Interestingly, tw
did not differ significantly between the two groups (LacZ:
9.6960.99 ms, N=9; CNTF: 13.4361.67 ms, N=6). Overall,
these results suggest that glial, but not neuronal, GTs are
potentiated by CNTF overexpression.
CNTF Is Neuroprotective against QA by Increasing
Glutamate Uptake
To address the involvement of GTs in CNTF neuroprotection,
slices were incubated in 30 mM DL-threo-b-benzyloxyaspartate
(TBOA), a wide spectrum GT inhibitor, before, during and after
the application of QA. This dose of TBOA slightly increased FP
amplitude in both groups, but such increase reached a steady state
15–20 min after drug application and was not significant (Fig. 4B).
In the presence of 30 mM TBOA, the higher FP recovery in
CNTF slices was no longer observed, because it was similar in the
two groups. After 45 min of QA washout, FP amplitude was
11610% and 666% of initial value in LacZ (N=4) and CNTF
(N=6) slices, respectively; Fig. 4B, C. This result shows that GTs
play a key role in the resilience of FP against QA excitotoxicity in
CNTF slices.
Discussion
In this study, we show that CNTF neuroprotective effects
against glutamate excitotoxicity do not rely on a direct action on
striatal MSNs and glutamate transmission, but are mediated by an
enhanced glutamate uptake in activated astrocytes.
A number of studies have demonstrated that CNTF is a potent
neuroprotective factor for striatal MSNs in animal HD models,
includingrodentsandprimates.CNTF wasdeliveredeitherthrough
minipumps [5], encapsulated genetically engineered cells [6,7,23],
or by gene transfer with adenoviruses [24] and lentiviruses [25].
Here we show a marked neuroprotective effect of lentiviral-
delivered CNTF against QA excitotoxicity in vivo (.75% neuronal
rescue), and we also provide the first in vitro electrophysiological
evidencethat slicesfromCNTFanimalsaremoreresistanttoQA.It
has been shown that intrastriatal QA injection dramatically
increases extracellular glutamate level [18,26], and that this
glutamate outflow plays a key role in QA-induced neurotoxicity
through the activation of both ionotropic and metabotropic
glutamate receptors [27]. Accordingly, we previously found that
the neuroprotective effect of CNTF was associated with a marked
reduction (.60%) of QA-induced increase in extracellular
glutamate in the rat striatum [12]. Here we show that FP recovery
during QA washout was significantly improved, suggesting that the
massive glutamate outflow triggered by QA is more efficiently
buffered in slices from CNTF-overexpressing rats [18].
CNTF binds to a tripartite receptor complex composed of the
specific CNTF receptor alpha (CNTFRa) and two signal transduc-
ers, gp130 and leukemia inhibitory factor receptor [28]. The fact
that CNTFRa is expressed at very low level in striatal neurons [29]
and that CNTF has no neuroprotective activity in an almost pure
neuronal culture system [30] suggests that this cytokine may act on
other cells than neurons. Indeed, our patch-clamp recordings from
striatal MSNs did not demonstrate any significant effect of CNTF at
both pre- and postsynaptic levels (glutamate release probability,
spontaneous activity and AMPA/NMDA receptor function).
Expression of ionotropic glutamate receptor subunits NR2A,
NR2B and GluR2, and of the vesicular glutamate transporter
VGLUT1 was also previously shown not to be altered by CNTF
[12]. Overall, these results suggest that CNTF does not modify
striatal glutamatergic synaptic transmission.
Figure 4. The neuroprotective effect of CNTF is mediated by
GTs. A: c-DGG has a significantly higher inhibitory effect in CNTF slices
compared to LacZ: the histogram represents the ratio between EPSC
amplitude in the presence of 0.5 mM c-DGG and in control conditions
(*p,0.05, Mann-Whitney test). Traces show representative EPSCs (HP=
-60 mV). B: in the presence of the GTs inhibitor TBOA, there is little and
similar FP recovery from QA excitotoxicity in both groups. C: summary
of FP amplitude data at t=45 min in the absence and in the presence
of 30 mM TBOA (*p,0.05, Mann-Whitney test).
doi:10.1371/journal.pone.0008550.g004
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GLT-1 and GLAST, and the neuronal transporter EAAC1 [13],
but astrocytes are responsible for the majority of extracellular
glutamate removal. We have recently shown that glial GTs are
involved in the handling of excess glutamate, for instance during
tetanic synaptic activity, rather than modulating corticostriatal
EPSCs [22]. Our present results using c-DGG and TBOA suggest
that CNTF enhances glutamate uptake and that such effect plays a
significant role in the resistance of striatal neurons to QA-induced
glutamate outflow. The fact that we did not observe significant
changes in EPSC tw in CNTF slices supports the involvement of
glial rather than neuronal GTs, since only the latter affect EPSC
kinetic [22]. Indeed, CNTF increases the glycosylation level of
GLAST and GLT-1, and redistributes them into raft micro-
domains in which glutamate uptake is more efficient [31] leading
to a net increase in the glutamate buffering capacity, while no
changes were observed for EAAC1 [12,31].
Reduction of GLT-1 and/or GLAST expression and function
has been reported in several neurodegenerative pathologies such
as Alzheimer’s disease [32], hippocampal sclerosis [33] and HD
[34]. Interestingly, glutamate uptake inhibition in the rat striatum
has been shown to trigger massive neuronal loss [35] mimicking
excitotoxic HD models [3], and the expression of a mutant form of
huntingtin decreases GLT-1 expression in transgenic HD mice
[36] and in patients [34]. Altogether, these observations stress the
role of GTs in HD and validate the concept of therapeutic
approaches aimed at enhancing their function.
In conclusion, our data suggest that CNTF neuroprotective
effects are mediated by astrocytes and support the notion that
neuroprotection against glutamate excitotoxicity can be success-
fully achieved by increasing the capacity of glutamate buffering
by astrocytes. Our findings further validate CNTF overexpression
as a neuroprotective strategy for the treatment of HD and
other neurological diseases characterized by glutamate-mediated
neurodegeneration.
Materials and Methods
Injection of Lentiviruses in Rats
Three-month-old male Lewis rats (weight ,300 g, IFFA Credo,
France) were used in this study. All animal experimental pro-
cedures were carried out in strict accordance with the recom-
mendations of the EEC (86/609/EEC) for care and use of
laboratory animals, and conformed to the ethical guidelines of the
French Ministry of Agriculture and Forests (Animal Health and
Protection Veterinary Service). We used self-inactivated lentivi-
ruses encoding either the human CNTF gene (lenti-CNTF) with
the export sequence of immunoglobulin, or the b-galactosidase
gene (lenti-LacZ) under the control of the mouse phosphoglycerate
kinase 1 promoter [12,25,37]. Lentiviruses were diluted in vehicle
[0.1 M phosphate buffer saline (PBS) with 1% bovine serum
albumin] at a final concentration of 100 ng p24/ml. Rats were
anesthetized with a mixture of ketamine (15 mg/kg) and xylazine
(1.5 mg/kg). Suspensions of lenti-CNTF or lenti-LacZ were
injected bilaterally into the striatum using a 10 ml Hamilton
syringe (Reno, NV, USA) via a 28 gauge blunt needle (stereotaxic
coordinates: AP +0.5 mm, L 63.0 mm from bregma, V 24.5 mm
from the dura, with tooth bar set at 23.3 mm). Rats received a
total volume of 2 ml of lenti-CNTF (CNTF rats), lenti-LacZ (LacZ
rats) or vehicle (Vehicle rats) per striatum at a rate of 0.2 ml/min.
At the end of injection, the needle was left in place for 1 min
before being slowly removed. The skin was sutured and rats were
allowed to recover. CNTF effects were stable for several months
without any sign of down-regulation.
Injection of QA in Rats and Immunohistology
A solution of QA (80 mM in 0.1 M PBS) was prepared from a
180 mM stock solution containing 30 mg of QA dissolved in
900 ml PBS and 100 ml NaOH 1 N. CNTF, LacZ and Vehicle rats
were anesthetized with a mixture of ketamine-xylazine, placed in a
stereotaxic frame and injected with 1 ml of 80 mM QA using a
blunt-tipped 25 gauge Hamilton syringe and the same stereotaxic
coordinates as for lentiviral injections. Each injection was made
over 1 min, and the needle was left in place 2 min before being
slowly withdrawn. Two weeks later, rats were transcardially
perfused with 4% paraformaldehyde under deep pentobarbital
anesthesia. Brains were postfixed in 4% paraformaldehyde for
24 h and cryoprotected in a sucrose solution. Coronal brain
sections (40 mm-thick) were cut on a freezing microtome, collected
serially and processed for Neuronal Nuclei protein immunohisto-
chemistry (NeuN, 1:10,000, Chemicon, Billerica, MA, USA) with
tyramine amplification [24]. Determination of the lesion volume
was made on digitized sections (interspace 200 mm) by manually
delineating the border of the lesion on each section. The total
volume was calculated according to the Cavalieri method [38].
Immunofluorescent Labeling
Staining was performed as described previously [12]. To
identify MSNs, 2 animals were co-injected with a lentivirus
encoding GFP (100 ng p24) and a lentivirus encoding CNTF or
LacZ (200 ng p24). The antibodies used were directed against
GFAP directly coupled to Cy3 (1:500, Sigma, Saint-Louis, MO,
USA) and against vimentin (1:1000, Calbiochem, Nottingham,
UK).
Slice Preparation and Drugs
Brains were cut with a vibratome in coronal corticostriatal slices
(250 mm) in ice-cold solution, whose composition was (in mM):
110 choline, 2.5 KCl, 1.25 NaH2PO4, 7 MgCl2, 0.5 CaCl2,2 5
NaHCO3, 7 glucose, pH=7.4 bubbled with O2/CO2 (95/5%).
Slices were then stored in artificial cerebrospinal fluid (ACSF),
whose composition was (in mM): 126 NaCl, 2.5 KCl, 1.2 MgCl2,
1.2 NaH2PO4, 2.4 CaCl2, 11 glucose, and 25 NaHCO3, pH=7.4,
gassed with O2/CO2, and containing 250 mM kynurenic acid and
1 mM sodium pyruvate. Recordings were performed at 35uCi n
standard ACSF solution (without kynurenic acid and sodium
pyruvate) gassed with O2/CO2. Drugs were from Tocris-Cookson
(Bristol, UK) and Sigma, and were dissolved in the perfusing
ACSF at the desired final concentration.
Electrophysiology and Data Analysis
Recordings were performed by AxoPatch 200B and Multiclamp
700B amplifiers with pClamp 10.2 software (Molecular Devices,
Sunnyvale, CA, USA). Synaptic stimulation for triggering
excitatory postsynaptic currents (EPSCs) and extracellular field
potentials (FPs) was delivered by a bipolar electrode placed in the
white matter between cortex and striatum. Whole-cell patch-
clamp microelectrodes (4–5 MV) were filled with a CsCl-based
solution, whose composition was (in mM): 140 CsCl, 10 NaCl, 0.1
CaCl2, 10 HEPES, 1 EGTA, 2 Mg-ATP and 0.5 Na-GTP,
pH=7.3. Striatal MSNs were visualized by infrared videomicro-
scopy before patching. Picrotoxin (50 mM) was always added to
the bath solution to block GABAA receptor-mediated synaptic
transmission. Neurons showing $20% change in series resistance
were discarded from the analysis. Extracellular recordings were
performed using electrodes filled with 2 M NaCl (,2M V). All
recordings were obtained from the dorsal striatum close to the
stimulating electrode, which delivered stimuli at 0.1 and 0.05 Hz
CNTF Enhances Glutamate Uptake
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Clampfit 10.2 (Molecular Devices, Sunnyvale, CA, USA), Origin
7.5 (Originlab Corp., Northampton, MA, USA) and MiniAnalysis
6.0 (Synaptosoft, Decatur, GA, USA). EPSCs measurements were
performed on samples of ten averaged traces, before and after
each drug treatment. Amplitude was measured by averaging a
0.3 ms time interval centered on the maximum amplitude value
(peak). Measurement of the AMPA and NMDA component of the
EPSC for calculating NMDA/AMPA ratio was performed at peak
for the AMPA component at a holding potential (HP) of 260 mV,
and for the NMDA component at +40 mV and 50 ms after the
stimulation artifact, when the AMPA component is negligible (see
Fig. 3C). This protocol allows such measurements without using
pharmacological blockers of ionotropic glutamate receptors,
leaving the possibility to use the same MSN for other
pharmacological tests [39]. FP amplitude was measured by
averaging three consecutive sweeps. The mean basal FP amplitude
was obtained by averaging a 10 min period before drug
application. Statistical tests are specified case by case and data
are presented as mean6SEM.
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